帕博利珠-话题@MedSci

#帕博利珠#

54篇内容 | 2051人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2056883, encodeId=33e520568837c, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, objectType=article, longId=212750, objectId=8752212e509b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8752212e509b, replyNumber=0, likeNumber=102, createdTime=2021-08-11, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8752212e509b, moduleTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8752212e509b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056882, encodeId=9ab52056882c0, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, objectType=article, longId=212747, objectId=5467212e47b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5467212e47b0, replyNumber=0, likeNumber=94, createdTime=2022-02-13, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5467212e47b0, moduleTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5467212e47b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056885, encodeId=02b6205688538, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Cancers：预测帕博利珠单抗（Pembrolizumab）治疗非小细胞肺癌患者持续应答的标志物和基因集, objectType=article, longId=215106, objectId=b85c215106cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b85c215106cc, replyNumber=0, likeNumber=97, createdTime=2021-11-11, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b85c215106cc, moduleTitle=Cancers：预测帕博利珠单抗（Pembrolizumab）治疗非小细胞肺癌患者持续应答的标志物和基因集, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b85c215106cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056873, encodeId=cf8620568e398, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, objectType=article, longId=205930, objectId=92a920593034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92a920593034, replyNumber=0, likeNumber=100, createdTime=2021-05-15, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92a920593034, moduleTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92a920593034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056881, encodeId=9b8e205688133, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, objectType=article, longId=212429, objectId=7a5c212429e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5c212429e5, replyNumber=0, likeNumber=62, createdTime=2021-06-08, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5c212429e5, moduleTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5c212429e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056879, encodeId=1a8020568e90b, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Clin Cancer Res：艾立布林联合帕博利珠单抗对转移性三阴性乳腺癌有效, objectType=article, longId=208835, objectId=da3a20883514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da3a20883514, replyNumber=0, likeNumber=77, createdTime=2021-08-27, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da3a20883514, moduleTitle=Clin Cancer Res：艾立布林联合帕博利珠单抗对转移性三阴性乳腺癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da3a20883514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056888, encodeId=a5ca2056888f6, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=NEJM：帕博利珠单抗治疗持续性、复发性或转移性宫颈癌（KEYNOTE-826研究）, objectType=article, longId=217406, objectId=cd4321e40665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd4321e40665, replyNumber=0, likeNumber=72, createdTime=2022-08-12, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd4321e40665, moduleTitle=NEJM：帕博利珠单抗治疗持续性、复发性或转移性宫颈癌（KEYNOTE-826研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd4321e40665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056880, encodeId=d00720568804d, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果, objectType=article, longId=211056, objectId=5c43211056a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c43211056a3, replyNumber=0, likeNumber=77, createdTime=2021-09-17, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c43211056a3, moduleTitle=Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c43211056a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056876, encodeId=922920568e653, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=JCO：帕博利珠单抗单药一线治疗晚期非透明细胞肾癌的客观缓解率可达26.7％, objectType=article, longId=206735, objectId=bdea206e35cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdea206e35cc, replyNumber=0, likeNumber=71, createdTime=2021-03-31, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdea206e35cc, moduleTitle=JCO：帕博利珠单抗单药一线治疗晚期非透明细胞肾癌的客观缓解率可达26.7％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdea206e35cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056874, encodeId=259c20568e4ac, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）, objectType=article, longId=205931, objectId=2ebe20593162, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ebe20593162, replyNumber=0, likeNumber=73, createdTime=2021-09-19, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ebe20593162, moduleTitle=ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ebe20593162)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056872, encodeId=021320568e21a, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, objectType=article, longId=204948, objectId=3cf1204948c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf1204948c8, replyNumber=0, likeNumber=85, createdTime=2021-09-10, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf1204948c8, moduleTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cf1204948c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056875, encodeId=9f9920568e55d, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效, objectType=article, longId=206110, objectId=c0bd206110aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0bd206110aa, replyNumber=0, likeNumber=79, createdTime=2021-03-26, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0bd206110aa, moduleTitle=复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0bd206110aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056877, encodeId=018e20568e765, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％, objectType=article, longId=206737, objectId=4e1b206e376a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e1b206e376a, replyNumber=0, likeNumber=85, createdTime=2021-07-10, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e1b206e376a, moduleTitle=JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e1b206e376a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056866, encodeId=09ed205686630, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=帕博利珠单抗食管癌免疫治疗中国人群数据公布, objectType=article, longId=180781, objectId=658f180e8133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=658f180e8133, replyNumber=0, likeNumber=63, createdTime=2020-01-22, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=658f180e8133, moduleTitle=帕博利珠单抗食管癌免疫治疗中国人群数据公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=658f180e8133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056863, encodeId=190820568633a, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Lancet Oncol：研究5年随访结果显示：帕博利珠单抗为晚期黑色素瘤患者带来长期生存获益, objectType=article, longId=177116, objectId=c4f01e7116dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4f01e7116dc, replyNumber=0, likeNumber=85, createdTime=2019-10-15, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4f01e7116dc, moduleTitle=Lancet Oncol：研究5年随访结果显示：帕博利珠单抗为晚期黑色素瘤患者带来长期生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4f01e7116dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056870, encodeId=2ad020568e023, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=中国晚期肺鳞癌患者迎一线治疗新标准，帕博利珠单抗新适应证获批意义重大, objectType=article, longId=183912, objectId=fc8b1839120b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc8b1839120b, replyNumber=0, likeNumber=62, createdTime=2020-02-28, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc8b1839120b, moduleTitle=中国晚期肺鳞癌患者迎一线治疗新标准，帕博利珠单抗新适应证获批意义重大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc8b1839120b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056869, encodeId=290a2056869ec, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=【2019 ESMO】放化疗联合帕博利珠单抗治疗局部晚期食管鳞癌, objectType=article, longId=181035, objectId=c7c318103504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7c318103504, replyNumber=0, likeNumber=73, createdTime=2020-04-20, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7c318103504, moduleTitle=【2019 ESMO】放化疗联合帕博利珠单抗治疗局部晚期食管鳞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7c318103504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056860, encodeId=4c6020568602c, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=帕博利珠单抗斩获小细胞肺癌治疗适应证, objectType=article, longId=168856, objectId=a17e168856d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a17e168856d1, replyNumber=0, likeNumber=106, createdTime=2019-12-15, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a17e168856d1, moduleTitle=帕博利珠单抗斩获小细胞肺癌治疗适应证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a17e168856d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056861, encodeId=bfe62056861e9, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位, objectType=article, longId=174829, objectId=8b6f1e482903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b6f1e482903, replyNumber=0, likeNumber=68, createdTime=2020-05-13, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b6f1e482903, moduleTitle=周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b6f1e482903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056862, encodeId=f6d32056862e7, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=帕博利珠单抗为胃癌一线治疗点亮希望, objectType=article, longId=175261, objectId=59071e526198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59071e526198, replyNumber=0, likeNumber=113, createdTime=2019-12-10, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59071e526198, moduleTitle=帕博利珠单抗为胃癌一线治疗点亮希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59071e526198)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

帕博利珠

2020-05-29

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189

2021-08-11

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性

2022-02-13

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Cancers：预测帕博利珠单抗（Pembrolizumab）治疗非小细胞肺癌患者持续应答的标志物和基因集

2021-11-11

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）

2021-05-15

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。

2021-06-08

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Clin Cancer Res：艾立布林联合帕博利珠单抗对转移性三阴性乳腺癌有效

2021-08-27

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

NEJM：帕博利珠单抗治疗持续性、复发性或转移性宫颈癌（KEYNOTE-826研究）

2022-08-12

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果

2021-09-17

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

JCO：帕博利珠单抗单药一线治疗晚期非透明细胞肾癌的客观缓解率可达26.7％

2021-03-31

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）

2021-09-19

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究

2021-09-10

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效

2021-03-26

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％

2021-07-10

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

帕博利珠单抗食管癌免疫治疗中国人群数据公布

2020-01-22

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Lancet Oncol：研究5年随访结果显示：帕博利珠单抗为晚期黑色素瘤患者带来长期生存获益

2019-10-15

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

中国晚期肺鳞癌患者迎一线治疗新标准，帕博利珠单抗新适应证获批意义重大

2020-02-28

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

【2019 ESMO】放化疗联合帕博利珠单抗治疗局部晚期食管鳞癌

2020-04-20

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

帕博利珠单抗斩获小细胞肺癌治疗适应证

2019-12-15

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位

2020-05-13

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

帕博利珠单抗为胃癌一线治疗点亮希望

2019-12-10

科室
- - 订阅+
  - 更多科室
工具
服务